Wright G L, Wilson E, Klinger M, Roland W, Beckett M L, Daddona P E
Department of Microbiology and Immunology, Eastern Virginia Medical School, Norfolk 23501.
Prostate. 1990;16(1):81-9. doi: 10.1002/pros.2990160109.
The subrenal capsule assay was used to determine if 125I-labeled anti-prostate monoclonal antibody TURP-27 could target human prostate tumor fragments implanted under the renal capsule of normal immunocompetent C57 BL/6 mice. Maximal binding and optimal tumor to non-tumor tissue ratios occurred within 24-48 hours postadministration of 125I-TURP-27. No significant localization was observed in mice bearing TURP-27 antigen-negative human colon tumor tissue implants or with an isotype-matched control monoclonal antibody. These preclinical data suggest that TURP-27 may have clinical application for imaging metastatic prostate tumors and further application in immunoconjugate and/or radiotherapy of prostate cancer.
采用肾包膜下测定法来确定125I标记的抗前列腺单克隆抗体TURP-27是否能够靶向植入正常具有免疫活性的C57 BL/6小鼠肾包膜下的人前列腺肿瘤片段。在给予125I-TURP-27后24 - 48小时内出现最大结合以及肿瘤与非肿瘤组织的最佳比例。在携带TURP-27抗原阴性的人结肠肿瘤组织植入物的小鼠或使用同型匹配对照单克隆抗体的小鼠中未观察到明显的定位。这些临床前数据表明,TURP-27可能在转移性前列腺肿瘤成像的临床应用以及前列腺癌免疫缀合物和/或放射治疗中具有进一步的应用。